Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Principia Biopharma Inc. (PRNB) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2020 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Amended and Restated Certificate of Incorporation of Principia Biopharma Inc",
"Second Amended and Restated Bylaws of Principia Biopharma Inc"
08/17/2020 8-K Quarterly results
08/06/2020 8-K Quarterly results
06/26/2020 8-K Quarterly results
06/12/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial Oral BTK inhibitor reaches primary endpoint in 50 percent of patients treated ³ 12 weeks; demonstrates fast onset and durable responses Principia to initiate pivotal Phase 3 trial in ITP"
06/09/2020 8-K Submission of Matters to a Vote of Security Holders
05/06/2020 8-K Quarterly results
Docs: "Principia Biopharma Reports First Quarter 2020 Financial Results"
04/24/2020 8-K Other Events
03/10/2020 8-K Quarterly results
02/06/2020 8-K Other Events
01/10/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Principia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated Diseases Company’s lead candidate PRN1008 receives generic name -- rilzabrutinib Rilzabrutinib to enter clinical trial in IgG4-Related Disease",
"Principia Announces Expansion of its BTK Franchise with PRN473 Topical Company expands focus on immune-mediated diseases and suspends FGFR program Company outlines anticipated key corporate milestones"
12/09/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 7, 2019 PRINCIPIA BIOPHARMA INC. Delaware 001-38653 26-3487603 220 East Grand Avenue, South San Francisco, California 94080 Registrant's Telephone Number, Including Area Code: 416-7700 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange A...",
"Principia Presents Consistent Positive Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial Investigational oral BTK inhibitor demonstrates rapid onset and increased treatment responses over time as well as a favorable tolerability profile in 31 patients who have no other treatment options",
"ITP Presentation"
11/05/2019 8-K Quarterly results
Docs: "Amended Code of Ethics and Business Conduct",
"Principia Biopharma Reports Third Quarter Financial Results"
10/18/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : October 15, 2019 Principia Biopharma Inc. Delaware 001-38653 26-3487603 220 East Grand Avenue, South San Francisco, California 94080 Registrant's Telephone Number, Including Area Code: 416-7700 Not applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange A...",
"Underwriting Agreement related to the Offering, among Principia Biopharma Inc., BofA Securities, Inc., SVB Leerink LLC, and Wells Fargo Securities, LLC",
"Opinion of Cooley LLP"
10/15/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : October 15, 2019 PRINCIPIA BIOPHARMA INC. Delaware 001-38653 26-3487603 220 East Grand Avenue, South San Francisco, California 94080 Registrant's Telephone Number, Including Area Code: 416-7700 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange A...",
"Principia Announces Positive Preliminary Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial Preliminary results from trial have been accepted as an oral presentation at upcoming American Society of Hematology Annual Meeting"
10/10/2019 8-K Quarterly results
08/30/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/08/2019 8-K Quarterly results
06/14/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 11, 2019 PRINCIPIA BIOPHARMA INC. Delaware 001-38653 26-3487603 220 East Grand Avenue, South San Francisco, California 94080 Registrant's telephone number, including area code: 416-7700 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-c..."
05/15/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 14, 2019 Principia Biopharma Inc. Delaware 001-38653 26-3487603 220 East Grand Avenue South San Francisco, California 94080 Registrant's Telephone Number, Including Area Code: 416-7700 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ...",
"Principia Biopharma Announces First Patient Dosed in Sanofi's Phase 2b Trial of SAR442168 in Multiple Sclerosis, Triggering $30 Million Milestone SOUTH SAN FRANCISCO, Calif., May 14, 2019 - Principia Biopharma Inc. , a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that the first patient has been dosed in its partner Sanofi's Phase 2b clinical trial of SAR442168 in patients with relapsing multiple sclerosis , triggering a $30 million milestone payment to Principia. SAR442168, formerly known as PRN2246, is a Bruton's tyrosine kinase inhibitor that crosses the human blood-brain barrier and modulates immune cell function in both the periphery and in the brain,..."
05/14/2019 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 10, 2019 Principia Biopharma Inc. Delaware 001-38653 26-3487603 220 East Grand Avenue South San Francisco, California 94080 Registrant's Telephone Number, Including Area Code: 416-7700 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ..."
05/07/2019 8-K Quarterly results
Docs: "Principia Biopharma Inc. Condensed Consolidated Statements of Operations Three Months Ended March 31, 2019 2018 Revenue $ 5,160 $ 11,449 Operating expenses: Research and development 15,523 8,761 General and administrative 4,508 2,156 Total operating expenses 20,031 10,917 Income from operations 532 Other income , net 1 Interest income 1,183 115 Net income $ $ 310 Net income attributable to common stockholders $ $ — Net income per share attributable to common stockholders Basic $ $ — Diluted $ $ — Weighted-average shares used to calculate net income per share attributable to common stockholders Basic 23,866,066 630,359 Diluted 23,866,066 1,170,670 Principia Biopharma Inc."
04/22/2019 8-K Material Modifications to Rights of Security Holders, Departure of Directors or Certain Officers; Election of Directors; Appo...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : April 16, 2019 PRINCIPIA BIOPHARMA INC. Delaware 001-38653 26-3487603 220 East Grand Avenue, South San Francisco, California 94080 Registrant's telephone number, including area code: 416-7700 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-..."
03/26/2019 8-K Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 26, 2019 Principia Biopharma Inc. Delaware 001-38653 26-3487603 220 East Grand Avenue, South San Francisco, California 94080 Registrant's Telephone Number, Including Area Code: 416-7700 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-..."
03/19/2019 8-K Quarterly results
Docs: "Principia Biopharma Inc."
03/13/2019 8-K Termination of a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 11, 2019 Principia Biopharma Inc. Delaware 001-38653 26-3487603 220 East Grand Avenue, South San Francisco, California 94080 Registrant's Telephone Number, Including Area Code: 416-7700 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-...",
"Principia Biopharma Reacquires Rights to Oral Immunoproteasome Program"
03/04/2019 8-K Quarterly results
02/28/2019 8-K Quarterly results
02/19/2019 8-K Quarterly results
02/04/2019 8-K Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : February 1, 2019 Principia Biopharma Inc. Delaware 001-38653 26-3487603 220 East Grand Avenue, South San Francisco, California 94080 Registrant's Telephone Number, Including Area Code: 416-7700 400 East Jamie Court, Suite 302, South San Francisco, California Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communic..."
12/19/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
11/06/2018 8-K Quarterly results
Docs: "Principia Biopharma Reports Third Quarter Financial Results"
10/29/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "400 East Jamie Court",
"Principia Biopharma Appoints Dolca Thomas, M.D. as Chief Medical Officer"
10/18/2018 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy